CorMedix provides business update, reaffirms 2026 revenue guidance and reports third-quarter cash position
CRMD•CorMedix reaffirmed its 2026 total revenue guidance and reported its third-quarter cash position. It expects the 2027 DefenCath add-on rate to exceed the current $2.37 rate in all quarters, with a decline in Q2 and an increase in Q3 and/or Q4 compared with Q2.
1. 2027 add-on rate outlook
CorMedix expects the DefenCath add-on rate to exceed the current $2.37 rate in all quarters of 2027. It anticipates the rate will decline in Q2 compared with Q1, then increase in Q3 and/or Q4 compared with Q2.
